The antibody-drug conjugate (ADC) field was one of the hottest dealmaking spaces of 2024 and Roche and Innovent Biologics have started the ball rolling again early in the new year, with a global licensing agreement worth up to $1bn.
Roche And Innovent Kick Off 2025 With ADC Lung Cancer Deal
The Swiss giant has made a New Year’s resolution to follow up its small cell lung cancer leader Tecentriq with an antibody drug conjugate.
More from Deals
More from Scrip
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.